case_images: PMC4634743_01
case_images: Transverse CT scan of the oral cavity showing an oral tumor at diagnosis (a) and 30 days after the initiation of bortezomib treatment (b)
case_images: 40364_2015_53_Fig1_HTML.jpg
case_images: PMC4634743_01_40364_2015_53_Fig1_HTML.jpg
case_images: Fig1
case_images: A computed tomography (CT) demonstrated a bulky tumor localized in the mucosa of the oral cavity (Fig. 1a), without enlargement of the systemic lymph nodes. One week after the initiation of bortezomib, a marked regression of the oral tumor was observed, and one month after its initiation, no significant swelling of the oral cavity was detected (Fig. 1b).
case_images: a Hematoxylin and eosin staining showing large lymphoid cells with centroblastic morphology (X400). Cells of the oral tumor (X200) were immunohistologically positive for b CD138 and c CD38, d MUM-1, and were negative for e CD20, f CD79a, g EBV-encoded RNA in situ hybridization (EBER-ISH) and h HHV8. i The Ki-67 proliferation index was almost 100 %
case_images: 40364_2015_53_Fig2_HTML.jpg
case_images: PMC4634743_01_40364_2015_53_Fig2_HTML.jpg
case_images: Fig2
case_images: Biopsy of the oral mass showed diffuse proliferation of large lymphoid cells (Fig. 2a) with centroblastic morphology, which were positive for CD138 (Fig. 2b), CD38 (Fig. 2c), CD56, and MUM-1 (Fig. 2d) and negative for CD20 (Fig. 2e), CD79a (Fig. 2f), CD3 and BCL-6. EBV-encoded RNA in situ hybridization (EBER-ISH) (Fig. 2g) and HHV8 (Fig. 2h) were negative. The Ki-67 proliferation index was almost 100 % (Fig. 2i).